Please assess the completion status of the following clinical trial:

Trial Title: Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-FDG and 82Rb PET/CT on PAH and CTEPH

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic PAH (PH group 1 Dana Point / stages 2 à 4 according to NYHA classification, defined by a mean arterial pulmonary pressure \>25 millimeter of mercury (mmHg) at rest, an occlusion arterial pulmonary pressure \<15 millimeter of mercury (mmHg) and vascular pulmonary resistance \>240 dyn.s.cm-5 for which a treatment with bosentan is indicated Or Patients with CTEPH not candidate for a pulmonary endarterectomy or patient with residual CTEPH after pulmonary endarterectomy (PH group 4 Dana Point / stages 2 to 4 according to NYHA classification) and for which a treatment with bosentan is indicated~* Indication to perform a right heart catheterization in the context of PAH suspected during cardiac ultrasound~* Age from 18 to 80 years old, male and female~* Karnofsky index ≥80%~* Informed consent signed~Exclusion Criteria:~* Patients with PAH stages 2,3 or 5 of Dana Point~* Patients with a contra-indication to adenosine including severe uncontrolled asthma, severe uncontrolled chronic obstructive pulmonary disease, 2nd or 3rd degree atrioventricular block without pacemaker,~* Patients with a contraindication to Bosentan, i.e :hypersensibility to the product, hepatic failure Child Pugh B or C, aminotransferases \>3 times normal value (N),association with cyclosporine A or glibenclamide~* Pregnancy, female of child-bearing potential not using any acceptable contraceptive method, breastfeeding~* Atrial fibrillation (Ventricular Ejection Fraction (VEF) not evaluable at echography)~* Karnofsky index \<80%~* Impossibility to obtain informed consent signed~* Left cardiopathies that can be responsible of post-capillar hypertension~* Involvement in another clinical study with an unregistered drug within 30 days prior to this specific study and during the entire course of the study~* Inability to comply with study procedures (linguistic problem, psychiatric problems, dementia, confusional state)~* Known or suspected non compliance drug or alcohol abuse~* Left heart assessment : diastolic and systolic function and valvular structures to exclude a cardiac pathology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).